Carvykti regimen extends PFS in advanced multiple myeloma

A phase 3 trial of ciltacabtagene autoleucel for adults with relapsed or refractory multiple myeloma met its primary endpoint, according to the agent’s manufacturer.Ciltacabtagene autoleucel (Carvykti; Janssen, Legend Biotech) — often called cilta-cel — is a B-cell...

Three-drug combination active in pretreated multiple myeloma

NEW ORLEANS — A novel combination induced response among patients with pretreated multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.The regimen — which consisted of teclistamab (JNJ-64007957, Janssen), subcutaneous daratumumab...